A Mitchell Phelps, PhD

College

College of Pharmacy

Academic Title

Assoc Professor

Research Program

Leukemia Research

Research Interest

Leukemia, Lymphocytic, Chronic, B-Cell, Cancer, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Biliary Tract Cancer, Lymphoma, Mantle-Cell

Dr. Phelps' expertise is in analytical methodologies and data modeling to study the disposition of novel anti-cancer agents. His lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).

Education and Background

Office Location

230 Parks Hall

500 W 12th Ave, Columbus, OH 43210

614-688-4370

phelps.32@osu.edu

Publications

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.

Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC

Leuk Lymphoma 58 2947-2951 12/01/2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration.

You J, Olencki T, Brooks TR, Vangundy Z, Wang J, Biesiadecki B, Branson OE, Yildiz V, Carson WE, Markowitz J, Stiff AR, Freitas MA, Papenfuss T, Foote IP, Tridandapani S, Yu L, Phelps MA

Sci Rep 7 15424 11/13/2017
PRMT5 as a druggable target for glioblastoma therapy.

Phelps M, Welker AM, Zhang J, Hsu S, Kaur B, Baiocchi R, Wang J, Li C, Zhou W, Imitola J, Beattie CE, Shi G, An M, Yang X, Banasavadi-Siddegowda YK

Neuro Oncol in press 11/02/2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58 2310-2318 10/01/2017
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y

PLoS Med 14 e1002382 09/01/2017
Influence of OATP1B1 Function on the Disposition of Sorafenib-ß-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD

Clin Transl Sci 10 271-279 07/01/2017
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.

Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC

Mol Carcinog 56 1722-1732 07/01/2017
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA

Clin Lymphoma Myeloma Leuk 17 347-353 06/01/2017
Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading.

Sutaria DS, Badawi M, Phelps MA, Schmittgen TD

Pharm Res 34 1053-1066 05/01/2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA, Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA

Clin Pharmacol Ther 012 511-19 02/04/2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA, Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA

Clin Pharmacol Ther 012 511-19 02/04/2017
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.

Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K, Chalmers J, Schmittgen TD, Phelps MA

J Extracell Vesicles 6 1324730 01/01/2017
Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery.

Sutaria DS, Jiang J, Elgamal OA, Pomeroy SM, Badawi M, Zhu X, Pavlovicz R, Azevedo-Pouly ACP, Chalmers J, Li C, Phelps MA, Schmittgen TD

J Extracell Vesicles 6 1333882 01/01/2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA

PLoS One 12 e0181885 01/01/2017
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.

Orienti I, Falconi M, Teti G, Currier MA, Wang J, Phelps M, Cripe TP

Pharm Res 33 2722-35 11/01/2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maddocks K, Hertlein E, Chen TL, Wagner AJ, Ling Y, Flynn J, Phelps M, Johnson AJ, Byrd JC, Jones JA

Leuk Lymphoma 57 2212-5 09/01/2016
In vitro immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes.

Rosas LE, Elgamal OA, Mo X, Phelps MA, Schmittgen TD, Papenfuss TL

J Immunotoxicol 13 652-65 09/01/2016
Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice.

Oberdick J, Ling Y, Phelps MA, Yudovich MS, Schilling K, Sadee W

J Pharmacol Exp Ther 358 22-30 07/01/2016
Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss CC, Phelps M, Rossman JS, Pei D, Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, Phelps MA, Rossman JS, Pei D

Biochemistry 55 2601-12 05/10/2016
Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss CC, Phelps M, Rossman JS, Pei D, Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, Phelps MA, Rossman JS, Pei D

Biochemistry 55 2601-12 05/10/2016
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N

Vet Comp Oncol in press 05/02/2016
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd

Cancer Immunol Res 4 323-336 04/01/2016
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd

Cancer Immunol Res 4 323-336 04/01/2016
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd

Cancer Immunol Res 4 323-336 04/01/2016
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd

Cancer Immunol Res 4 323-336 04/01/2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM, Paulaitis ME, Freitas MA, Pichiorri F, Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

J Proteomics 136 89-98 03/16/2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM, Paulaitis ME, Freitas MA, Pichiorri F, Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

J Proteomics 136 89-98 03/16/2016
Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Phelps M, Coss C, Wang H, Cook M, Reproducibility Project: Cancer Biology, Reproducibility Project Cancer Biology

Elife 5 03/01/2016
Discovery of Anticancer Agents of Diverse Natural Origin.

Kinghorn AD, DE Blanco EJ, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, Phelps MA, Xu L, Zhang X, Shen YY

Anticancer Res 36 5623-5637 01/01/2016
Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK

AAPS J 18 737-45 01/01/2016
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N

Exp Hematol 43 770-4.e2 09/01/2015
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N

Exp Hematol 43 770-4.e2 09/01/2015
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.

Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T

Sci Rep 5 12122 07/10/2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA

Br J Haematol 169 701-10 06/01/2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA

Br J Haematol 169 701-10 06/01/2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.

Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R

Blood 125 2689-92 04/23/2015
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA

Am J Hematol 90 327-33 04/01/2015
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.

Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N

Leukemia 29 346-55 02/01/2015
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.

Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ

Blood 125 284-95 01/08/2015
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA

Leuk Lymphoma 56 2834-40 01/01/2015
Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors.

Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, Dalton JT

J Am Anim Hosp Assoc 50 390-5 11/01/2014
Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.

Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MA

J Pharm Biomed Anal 98 160-5 09/01/2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.

Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA

Leuk Res 38 1025-9 09/01/2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.

Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MA

Clin Pharmacol Ther 96 182-91 08/01/2014
Race and ethnicity in cancer therapy: what have we learned?

Grenade C, Phelps MA, Villalona-Calero MA

Clin Pharmacol Ther 95 403-12 04/01/2014
A phase I trial of flavopiridol in relapsed multiple myeloma.

Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC

Cancer Chemother Pharmacol 73 249-57 02/01/2014
A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.

Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy N

Nanomedicine 10 393-400 02/01/2014
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MA

J Pharm Biomed Anal 88 262-8 01/01/2014
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.

Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC

Am J Hematol 89 19-24 01/01/2014
Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University.

Kitzmiller JP, Phelps MA, Neidecker MV, Apseloff G

Adv Med Educ Pract 5 191-6 01/01/2014
Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MF

Bioconjug Chem 24 1945-54 11/20/2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM

Leuk Res 37 1195-9 10/01/2013
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.

Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W

Leuk Lymphoma 54 1996-2002 09/01/2013
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.

Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA

Clin Pharmacokinet 52 705-12 08/01/2013
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T

Invest New Drugs 31 685-95 06/01/2013
Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes.

Zhou C, Zhang Y, Yu B, Phelps MA, Lee LJ, Lee RJ

Nanomedicine 9 504-13 05/01/2013